tirzepatide ema approval 2025: 38 Novel Drugs Approved, Top 3 Include Zurzuvae, Tvidak, Tryngolza | Joanna Sadowska, PhD, EMBA posted on the topic Obesity is increasingly addressed with

Phase 3 trial data from 604 adults in China showed weight loss of up to 19.3 percent at 48 weeks Comparable trials of Zepbound reported up to 20.9 percent weight loss at 72 weeks Hansoh reported lower rates of nausea and vomiting, suggesting potential tolerability advantages Regeneron is now planning a global phase 3 registrational program and is exploring combination therapy with its PCSK9 inhibitor Praluent

The SURMOUNT-1 trial showed 22.5% average body weight reduction at 15mg, with over half of participants losing more than 20% of their body weight

Data remains protected through HIPAA-aligned infrastructure, strong encryption, and minimal retention

[DOI] [PMC free article] [PubMed] [Google Scholar] 65.Nutrients, nutraceuticals, and xenobiotics affecting renal health

Fatty meats

Your diet and activity level can also increase the risk of developing high blood pressure